---
title: "Barings BDC | 8-K: FY2025 Q4 Revenue Beats Estimate at USD 67.97 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/276379020.md"
datetime: "2026-02-19T21:17:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276379020.md)
  - [en](https://longbridge.com/en/news/276379020.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276379020.md)
---

# Barings BDC | 8-K: FY2025 Q4 Revenue Beats Estimate at USD 67.97 M

Revenue: As of FY2025 Q4, the actual value is USD 67.97 M, beating the estimate of USD 67.66 M.

EPS: As of FY2025 Q4, the actual value is USD 0.24, missing the estimate of USD 0.2625.

EBIT: As of FY2025 Q4, the actual value is USD 50.18 M.

The provided Form 8-K filing, dated February 19, 2026, for Barings BDC, Inc. announces the issuance of a press release and supplemental investor presentation detailing financial results for the quarter and year ended December 31, 2025. However, this Form 8-K document does not contain specific financial and operational metrics, such as segment revenue, net income, gross margin, operating profit, operating costs, cash flow, or any forward-looking outlook or guidance. These details are stated to be available in the referenced press release (Exhibit 99.1) and investor presentation.

### Related Stocks

- [BBDC.US](https://longbridge.com/en/quote/BBDC.US.md)

## Related News & Research

- [ZAWYA: Barings opens office in Abu Dhabi to strengthen Middle East presence](https://longbridge.com/en/news/282964700.md)
- [Barings BDC  ( BBDC )  Beats Q3 Earnings and Revenue Estimates](https://longbridge.com/en/news/264766396.md)
- [On Semiconductor Pops on Analyst Upgrade. Should You Buy ON Stock Here?](https://longbridge.com/en/news/282585925.md)
- [Key facts: GSK’s Mo‑Rez 62%/67% responses; alpibectir in Phase‑2b and Phase‑2 meningitis](https://longbridge.com/en/news/282607697.md)
- [Barings' private credit fund limits withdrawals after redemption requests surge](https://longbridge.com/en/news/281764656.md)